These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 27254543)

  • 21. Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension.
    Rhodes CJ; Wharton J; Boon RA; Roexe T; Tsang H; Wojciak-Stothard B; Chakrabarti A; Howard LS; Gibbs JS; Lawrie A; Condliffe R; Elliot CA; Kiely DG; Huson L; Ghofrani HA; Tiede H; Schermuly R; Zeiher AM; Dimmeler S; Wilkins MR
    Am J Respir Crit Care Med; 2013 Feb; 187(3):294-302. PubMed ID: 23220912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Noninvasive Prognostic Biomarkers for Left-Sided Heart Failure as Predictors of Survival in Pulmonary Arterial Hypertension.
    Simpson CE; Damico RL; Hassoun PM; Martin LJ; Yang J; Nies MK; Vaidya RD; Brandal S; Pauciulo MW; Austin ED; Ivy DD; Nichols WC; Everett AD
    Chest; 2020 Jun; 157(6):1606-1616. PubMed ID: 31987881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).
    Benza RL; Miller DP; Gomberg-Maitland M; Frantz RP; Foreman AJ; Coffey CS; Frost A; Barst RJ; Badesch DB; Elliott CG; Liou TG; McGoon MD
    Circulation; 2010 Jul; 122(2):164-72. PubMed ID: 20585012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomarkers of Pulmonary Hypertension Are Altered in Children with Down Syndrome and Pulmonary Hypertension.
    Griffiths M; Yang J; Vaidya D; Nies M; Brandal S; Ivy DD; Hickey F; Wolter-Warmerdam K; Austin ED; Mullen M; Pauciulo MW; Lutz KA; Rosenzweig EB; Hirsch R; Yung D; Nichols WC; Everett AD
    J Pediatr; 2022 Feb; 241():68-76.e3. PubMed ID: 34687693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival in rheumatoid arthritis-associated pulmonary arterial hypertension compared with idiopathic pulmonary arterial hypertension.
    Sadeghi S; Granton JT; Akhavan P; Pasarikovski CR; Roos AM; Thenganatt J; Moric J; Johnson SR
    Respirology; 2015 Apr; 20(3):481-7. PubMed ID: 25583377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploratory analysis of the neutrophil to lymphocyte ratio in patients with pulmonary arterial hypertension.
    Harbaum L; Baaske KM; Simon M; Oqueka T; Sinning C; Glatzel A; Lüneburg N; Sydow K; Bokemeyer C; Klose H
    BMC Pulm Med; 2017 Apr; 17(1):72. PubMed ID: 28446163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of serum creatinine with abnormal hemodynamics and mortality in pulmonary arterial hypertension.
    Shah SJ; Thenappan T; Rich S; Tian L; Archer SL; Gomberg-Maitland M
    Circulation; 2008 May; 117(19):2475-83. PubMed ID: 18458173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
    Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F
    Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiogenic and inflammatory biomarkers in the differentiation of pulmonary hypertension.
    Säleby J; Bouzina H; Lundgren J; Rådegran G
    Scand Cardiovasc J; 2017 Oct; 51(5):261-270. PubMed ID: 28776404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CXC-chemokine ligand 10 in idiopathic pulmonary arterial hypertension: marker of improved survival.
    Heresi GA; Aytekin M; Newman J; Dweik RA
    Lung; 2010 Jun; 188(3):191-7. PubMed ID: 20186422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sensitive cardiac troponin I predicts poor outcomes in pulmonary arterial hypertension.
    Heresi GA; Tang WH; Aytekin M; Hammel J; Hazen SL; Dweik RA
    Eur Respir J; 2012 Apr; 39(4):939-44. PubMed ID: 21885398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Osteopontin in patients with idiopathic pulmonary hypertension.
    Lorenzen JM; Nickel N; Krämer R; Golpon H; Westerkamp V; Olsson KM; Haller H; Hoeper MM
    Chest; 2011 May; 139(5):1010-1017. PubMed ID: 20947652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study.
    Thakkar V; Stevens W; Prior D; Rabusa C; Sahhar J; Walker JG; Roddy J; Lester S; Rischmueller M; Zochling J; Nash P; Gabbay E; Youssef P; Proudman SM; Nikpour M
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):129-136. PubMed ID: 27214686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. p53 and hepatoma-derived growth factor expression and their clinicopathological association with Ewing family tumour.
    Yang Y; Zhen T; Zhang F; Dai S; Kang L; Liang Y; Xue L; Han A
    J Clin Pathol; 2014 Mar; 67(3):235-42. PubMed ID: 24072730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Soluble ST2 and N-terminal pro-brain natriuretic peptide combination. Useful biomarker for predicting outcome of childhoodpulmonary arterial hypertension.
    Chida A; Sato H; Shintani M; Nakayama T; Kawamura Y; Furutani Y; Inai K; Saji T; Matsuoka R; Nonoyama S; Nakanishi T
    Circ J; 2014; 78(2):436-42. PubMed ID: 24304538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Equivalency of Multiple Biomarkers to Clinical Pulmonary Arterial Hypertension Survival Risk Models.
    Griffiths M; Simpson CE; Yang J; Vaidya D; Nies MK; Brandal S; Damico R; Hassoun P; Ivy DD; Austin ED; Pauciulo MW; Lutz KA; Martin LJ; Rosenzweig EB; Benza RL; Nichols WC; Manlhiot C; Everett AD
    Chest; 2024 Dec; 166(6):1511-1531. PubMed ID: 39154795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The association of the N-terminal pro-brain-type natriuretic peptide response to exercise with disease severity in therapy-naive pulmonary arterial hypertension: a cohort study.
    Kutsch J; Faul C; von Scheidt W; Schwaiblmair M; Berghaus TM
    Respir Res; 2018 Jan; 19(1):8. PubMed ID: 29334941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elevation of plasma cell-free hemoglobin in pulmonary arterial hypertension.
    Brittain EL; Janz DR; Austin ED; Bastarache JA; Wheeler LA; Ware LB; Hemnes AR
    Chest; 2014 Dec; 146(6):1478-1485. PubMed ID: 24945582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pulsatile haemodynamic parameters are predictors of survival in paediatric pulmonary arterial hypertension.
    Douwes JM; Roofthooft MT; Bartelds B; Talsma MD; Hillege HL; Berger RM
    Int J Cardiol; 2013 Sep; 168(2):1370-7. PubMed ID: 23340486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tissue Doppler imaging predicts adverse outcome in children with idiopathic pulmonary arterial hypertension.
    Takatsuki S; Nakayama T; Jone PN; Wagner BD; Naoi K; Ivy DD; Saji T
    J Pediatr; 2012 Dec; 161(6):1126-31. PubMed ID: 22748515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.